Navigation Links
Tapestry Receives Notice Regarding Minimum Bid Price Rule
Date:12/21/2007

BOULDER, Colo., Dec. 21 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) today announced that it received notice on December 18, 2007 from the Nasdaq Stock Market that the minimum bid price of its common stock had fallen below $1.00 for 30 consecutive business days and that Tapestry was therefore not in compliance with Marketplace Rule 4310(c)(4). In accordance with the Nasdaq Marketplace Rule 4310(c)(8)(D), Tapestry has until June 16, 2008, which is 180 calendar days from December 18, 2007, to regain compliance. This notification does not have immediate affect on the listing of the Company's common stock.

Tapestry can regain compliance with the minimum bid price rule if the bid price of its common stock closes at $1.00 or higher for a minimum of ten consecutive business days during the initial 180-day period, although Nasdaq may, in its discretion, require Tapestry to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days (but generally no more than 20 consecutive business days) before determining that Tapestry has demonstrated the ability to maintain long-term compliance. If compliance is not achieved by June 16, 2008, Tapestry will be eligible for an additional 180-day compliance period if it meets the Nasdaq Capital Market initial listing criteria as set forth in Marketplace Rule 4310(c) other than the minimum bid price requirement. If Tapestry is not eligible for an additional compliance period, or does not regain compliance during any additional compliance period, Nasdaq will provide written notice to Tapestry that its securities will be delisted. At such time, Tapestry would be able to appeal the delisting determination to a Nasdaq Listing Qualification
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
2. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
7. IsoTis Receives FDA Clearance for Accell Family of Products
8. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
11. XTL Receives Staff Letter From NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... DuPont Tate & Lyle Bio ... it has appointed Skidmore Sales & Distributing ... Essex Grain Products and Processor’s ... in the food and beverage markets. The ... mid-western states: Alabama, Arkansas, Connecticut, Delaware, Florida, ...
(Date:9/11/2014)... LONDON , Sept. 11, 2014 ... (CRT), the charity,s development and commercialisation arm, have reached ... biotechnology company in the emerging field of regenerative ... AST-VAC2 into clinical trials in subjects with non-small ... tenth treatment to enter Cancer Research UK,s Clinical ...
(Date:9/11/2014)... The Stem Cell Institute, located in ... umbilical cord stem cell therapy on Saturday, September 20, 2014 ... Resort from 1:00 pm to 4:00 pm. , Stem ... – “Umbilical Cord Stem Cell Clinical Trials for MS and ... founder of the Stem Cell Institute and Medistem Panama Inc. ...
(Date:9/10/2014)... Brunswick, New Jersey (PRWEB) September 11, 2014 ... will host its annual Innovations in Dermatological Sciences ... meeting will focus on how the university, industry ... dermatological research into clinical use. , This conference ... had experience with cross-sector collaboration, to share their ...
Breaking Biology Technology:DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 2DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 4Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 5Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 6Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 7Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 8Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 2Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 3Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 4Innovations in Dermatological Sciences 2014 2Innovations in Dermatological Sciences 2014 3
... N.J., March 26 Vicus Therapeutics, LLC, ... Rao, Vice President Clinical Research and Development, ... 15th International,Molecular Medicine Tri-Conference on March 28st ... Convention Center in San Francisco. Dr. Rao ...
... JOLLA, Calif., March 26 TorreyPines,Therapeutics, Inc. (Nasdaq: ... and year ended December 31, 2007. For the full ... a net loss of $23.4 million.,Cash and cash equivalents ... made meaningful progress in our three clinical development programs,in ...
... 26 Pharsight,Corporation (Nasdaq: PHST ), a leading ... clinical drug,development announced today that it will be presenting ... Conference on April 2, 2008 at the Palms Las,Vegas. ... Vice President and CFO, will be presenting on April ...
Cached Biology Technology:TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 2TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 3TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 4TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 5TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 6TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 7Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference 2
(Date:9/11/2014)... DDT, American peregrine falcons ( Falco peregrines anatum ) ... stop rearing young birds in captivity and placing them ... models that year in ESA,s journal Ecological ... in California, with and without direct human intervention in ... would continue to recover without captive rearing, though the ...
(Date:9/11/2014)... 2014)Scientists today unveiled what appears to be the first ... New fossils of the massive Cretaceous-era predator reveal it ... years ago, providing the most compelling evidence to date ... an aquatic environment. The fossils also indicate that ... roam the Earth, measuring more than 9 feet longer ...
(Date:9/11/2014)... ago, a sudden, catastrophic event plunged much of the ... drought. This drastic climate changethe Younger Dryascoincided with the ... and the mastodon, and resulted in major declines in ... culture. , With limited evidence, several rival theories have ... such as a collapse of the North American ice ...
Breaking Biology News(10 mins):Volunteer 'eyes on the skies' track peregrine falcon recovery in California 2Volunteer 'eyes on the skies' track peregrine falcon recovery in California 3Volunteer 'eyes on the skies' track peregrine falcon recovery in California 4Volunteer 'eyes on the skies' track peregrine falcon recovery in California 5Scientists report first semiaquatic dinosaur, Spinosaurus 2Scientists report first semiaquatic dinosaur, Spinosaurus 3Scientists report first semiaquatic dinosaur, Spinosaurus 4Microscopic diamonds suggest cosmic impact responsible for major period of climate change 2
... A large collaborative study has added to the ... a person will be. The research, published by Cell ... of Human Genetics , identifies uncommon and previously unknown ... the genetic architecture of other complex traits. Although ...
... Most agricultural crops require large quantities of ... for growers is finding ways to balance the ... potentially harmful nitrates that can leach into ground ... "low-input" approaches is challenging researchers to identify genotypes ...
... traditionally relied heavily on hand thinning, a necessary but ... costs and a limited workforce, peach and other stone ... string thinners to minimize the need for hand thinning. ... when it was evaluated in four U.S. growing regions; ...
Cached Biology News:Large-scale analysis identifies new genetic alterations associated with height 2Improving nitrogen use efficiency lessens environmental impact 2Hybrid string blossom thinner tested in peach orchards 2
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Indoleamine 2,3-dioxygenase [IDO]...
Request Info...
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Biology Products: